A groundbreaking clinical trial supported by University Hospital Geneva is currently recruiting participants to investigate breathlessness patterns in patients with cancer, chronic obstructive pulmonary disease (COPD), and heart failure. Through immersive virtual reality and cerebral fMRI techniques, the study aims to unveil the neural mechanisms underlying breathlessness across these medical conditions.
What changed?
The study, officially titled “Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study,” marks a novel approach by combining advanced imaging methods with immersive virtual reality. Researchers aim to identify whether similar neurological correlates of breathlessness exist across cancer, COPD, and heart failure patients, and compare these findings to healthy volunteers. This distinctive focus offers more precise insights into patient experiences and may eventually inform treatment pathways.
What does the study involve?
Study participants and settings
The trial is open to individuals with cancer, COPD, or heart failure, as well as volunteers without these conditions. Participants undergo cerebral fMRI scans to observe brain activity linked to their breathlessness episodes.
Innovative tools
The use of immersive virtual reality allows researchers to simulate scenarios that may provoke sensations of breathlessness. By coupling these simulations with fMRI, the team can map the brain regions activated during these experiences.
Research goals
The primary goal of the study is to validate the feasibility of using this combined methodology to study breathlessness. Secondary outcomes may include identifying potential intervention points for improving patient quality of life and reduced healthcare burdens.
What could these findings mean?
If successful, the results may redefine the understanding of how patients’ brains process breathlessness as a symptom of complex, chronic illnesses. This could directly impact future device innovations and interventions targeting symptom relief in oncology, pulmonology, and cardiology domains.
Regulatory and quality teams in the medical device industry should monitor the outcomes closely. Findings could influence clinical applications of imaging techniques and virtual reality in therapeutic settings. The potential links to neurological patterns may also create opportunities for novel device design and regulatory approval processes.
FAQ
1. Who is funding this trial?
The clinical trial is sponsored by University Hospital Geneva.
2. Who can participate?
The study is recruiting patients with cancer, COPD, or heart failure, as well as healthy volunteers.
3. How are breathlessness patterns studied?
The study combines cerebral fMRI imaging with simulations delivered via immersive virtual reality to analyze brain activity during breathlessness episodes.
4. How can this study impact medical devices?
The findings could influence the development of devices designed to manage symptoms of breathlessness by identifying neural targets for intervention.
Conclusion
The combination of fMRI imaging and virtual reality technology in studying breathlessness offers an exciting avenue for scientific and clinical advancements. Professionals in clinical research and medical device regulation are encouraged to follow this endeavor for its implications on future methodologies and potential innovations.
Disclaimer
This article is intended for clinicians, regulatory specialists, and quality teams. It is not a substitute for legal advice or professional consultation.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07319039?term=medical+device